ScripChinese drug makers have made both major cuts and additions to their R&D pipelines in recent months, including for antibody-drug conjugates (ADCs) amid increasingly fierce competition, a Scrip revie
In VivoIncluded for 2024 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, as well as individuals driving unique health initiatives worldwide. The 30 people below h